The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

Chandini Portteus named president and CEO of LIVESTRONG Foundation

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

CHANDINI PORTTEUS was named president and CEO of LIVESTRONG Foundation.

Portteus most recently served as chief mission officer at Susan G. Komen For The Cure, where she was instrumental in creating initiatives involving more than 30 countries. Her global programming work included fundraising with major donors and partnerships Fortune 100 companies.

In addition, she was the architect and relationship manager for the scientific advisory bodies of Susan G. Komen, which included the Scientific Advisory Board and the Komen Scholars.

Previously, she worked in sales for Knoll Pharmaceutical, as well as conducting clinical research at UT Southwestern Medical School, Children’s Medical Center, UT Houston School of Public Health and Parkland Hospital.

Table of Contents

YOU MAY BE INTERESTED IN

News Analysis

HHS presents new protein-forward dietary guidelines, turning the food pyramid upside down
The Kennedy guidelines are mum on cancer risks associated with red meat and alcohol

Recently, HHS Secretary Robert F. Kennedy Jr. posted a video montage featuring himself shirtless in jeans, working out with Kid Rock. The duo is in a blue-lit grotto with a cold plunge and sauna. Set to Kid Rock’s “Bawitdaba” and intercut with a selection of patriotic imagery, the video ends with the two men in a hot tub, chugging what appears to be milk.
By Claire Marie Porter
Guest Editorial

FDA’s guidance on MRD in MM goes beyond the ODAC vote—and that’s where it matters most
Draft guidance consolidates trial design updates for developers

In January, FDA released a draft guidance entitled “Minimal Residual Disease and Complete Response in Multiple Myeloma: Use as Endpoints to Support Accelerated Approval.” This release came roughly 20 months after the Oncologic Drugs Advisory Committee (ODAC) voted unanimously that minimal residual disease (MRD) negativity, in combination with complete response (CR), is an acceptable primary endpoint to support accelerated approval for multiple myeloma (MM) therapies. 
By Nicholas Richardson
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account